Literature DB >> 17478618

Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease.

Sanjay Sethi1, Rohin Sethi, Karen Eschberger, Phyllis Lobbins, Xueya Cai, Brydon J B Grant, Timothy F Murphy.   

Abstract

RATIONALE: Increased bacterial concentration (load) in the lower airways and new bacterial strain acquisition have been posited as mechanisms for chronic obstructive pulmonary disease (COPD) exacerbations. Bacterial concentrations are higher during exacerbation than during stable disease; however, these studies are cross sectional and devoid of strain typing.
OBJECTIVES: To determine if the increased bacterial concentrations function as a separate mechanism for exacerbation induction independent of new strain acquisition.
METHODS: In a prospective, longitudinal cohort of patients with COPD, the relationship between exacerbation occurrence, sputum bacterial concentrations, and new strain acquisition was examined.
MEASUREMENTS AND MAIN RESULTS: Clinical information, quantitative sputum cultures, and molecular typing of potential bacterial pathogen isolates. Over 81 months, 104 subjects completed 3,009 clinic visits, 560 (19.6%) during exacerbations and 2,449 (80.4%) during stable disease. Among preexisting strains, sputum concentrations of Nontypeable Haemophilus influenzae and Haemophilus haemolyticus were not different in exacerbation versus stable disease. Moraxella catarrhalis (stable, 10(8.38 +/- 0.13) [mean +/- SEM] vs. exacerbation, 10(7.78 +/- 0.26); p = 0.02) and Streptococcus pneumoniae (stable, 10(8.42 +/- 0.21) vs. exacerbation, 10(7.76 +/- 0.52); p = 0.07) concentrations were lower during exacerbations compared with stable periods. Concentrations of new strains of H. influenzae (stable, 10(7.28 +/- 0.15) vs. exacerbation, 10(7.76 +/- 0.17); p = 0.04) and M. catarrhalis (stable, 10(7.85 +/- 0.15) vs. exacerbation, 10(8.37 +/- 0.14); p = 0.02), were increased during exacerbations; however, the differences were small.
CONCLUSIONS: Change in bacterial load is unlikely to be an important mechanism for exacerbations. Better understanding of the host-pathogen interaction, rather than enumerating bacteria in respiratory samples, is required to provide new insights into bacterial infection in COPD.

Entities:  

Mesh:

Year:  2007        PMID: 17478618     DOI: 10.1164/rccm.200703-417OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  60 in total

1.  [Antimicrobial treatment of patients with severe acute exacerbation of COPD].

Authors:  B Klapdor; S Ewig
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-22       Impact factor: 0.840

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 3.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

4.  Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.

Authors:  Christopher J Harvey; Rajesh K Thimmulappa; Sanjay Sethi; Xiaoni Kong; Lonny Yarmus; Robert H Brown; David Feller-Kopman; Robert Wise; Shyam Biswal
Journal:  Sci Transl Med       Date:  2011-04-13       Impact factor: 17.956

5.  Binding of human factor H to outer membrane protein P5 of non-typeable Haemophilus influenzae contributes to complement resistance.

Authors:  Jeroen D Langereis; Marien I de Jonge; Jeffrey N Weiser
Journal:  Mol Microbiol       Date:  2014-08-18       Impact factor: 3.501

6.  Lipooligosaccharides containing phosphorylcholine delay pulmonary clearance of nontypeable Haemophilus influenzae.

Authors:  Bing Pang; Dana Winn; Ryan Johnson; Wenzhou Hong; Shayla West-Barnette; Nancy Kock; W Edward Swords
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

Review 7.  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Authors:  Barbara P Yawn; Ibrahim Raphiou; Judith S Hurley; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

8.  Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Alicia Marín; Eduard Monsó; Sara Vilà; Cristian de la Roza; Ramona Hervás; Cristina Esquinas; Marian García; Laura Millares; Josep Morera; Antoni Torres
Journal:  Respir Res       Date:  2010-05-14

9.  The TGF-beta-pseudoreceptor BAMBI is strongly expressed in COPD lungs and regulated by nontypeable Haemophilus influenzae.

Authors:  Daniel Drömann; Jan Rupp; Kristina Rohmann; Sinia Osbahr; Artur J Ulmer; Sebastian Marwitz; Kristina Röschmann; Mahdi Abdullah; Holger Schultz; Ekkehard Vollmer; Peter Zabel; Klaus Dalhoff; Torsten Goldmann
Journal:  Respir Res       Date:  2010-05-31

Review 10.  Chronic obstructive pulmonary disease: an update on diagnosis and management issues in older adults.

Authors:  Shoab A Nazir; Marcia L Erbland
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.